Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 29681 results found since Jan 2013.
Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer
CONCLUSION: The current findings suggest an oncogenic role for STEAP4 in GC, with significantly high levels being associated with poor prognosis. Investigation of the GC tumor microenvironment suggests the potential function of STEAP4 is connected with the infiltration of diverse immune cells, which may contribute to the regulation of the tumor microenvironment. In conclusion, STEAP4 may serve as a potential therapeutic target for GC to improve the immune infiltration, as well as serve as a prognostic biomarker for judging the prognosis and immune infiltration status of GC.PMID:37700807 | PMC:PMC10494559 | DOI:10.5306/wjco.v14.i8.297
Source: Clinical Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Ze-Xuan Fang Yan-Yu Hou Zheng Wu Bing-Xuan Wu Yu Deng Hua-Tao Wu Jing Liu Source Type: research
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy
Adv Cancer Res. 2023;160:253-315. doi: 10.1016/bs.acr.2023.03.005. Epub 2023 Apr 20.ABSTRACTCurrent treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene therapy represents a targeted approach that in principle could significantly reduce undesirable side effects in normal tissues while significantly inhibiting tumor growth and progression. To be effective, this strategy requires a clear understanding of the molecular biology of cancer development and evolution and develo...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Amit Kumar Swadesh K Das Luni Emdad Paul B Fisher Source Type: research
Head and neck cancer treatment in the era of molecular medicine
Adv Cancer Res. 2023;160:205-252. doi: 10.1016/bs.acr.2023.03.004. Epub 2023 Apr 12.ABSTRACTHead and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Current multimodal treatment concepts combine surgery, chemotherapy, irradiation, immunotherapy, and targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of HNSCC and revealed novel therapeutic targets and prognostic/predictive biomarkers. Notably, HNSCC is characterized b...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Subramanya Pandruvada Remi Kessler Ann Thai Source Type: research
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
This study aimed to investigate whether the therapeutic benefits of tumor-targeting Claudin18.2 BiTE can be augmented by combining cancer selectively and immune-potentiating effects of OVs. Claudin18.2/CD3 BiTE was inserted into herpes simplex virus type 1 (HSV-1) to construct an OV-BiTE. Its expression and function were assessed using reporter cells and peripheral blood mononuclear cell (PBMC) co-culture assays. Intratumoral application of OV-BiTE restrained tumor growth and prolonged mouse survival compared with the unarmed OV in xenograft models and syngeneic mice bearing CLDN18.2-expressing KPC or Pan02 pancreatic canc...
Source: Herpes - September 13, 2023 Category: Infectious Diseases Authors: Shiyu Liu Fan Li Li Deng Qiongqiong Ma Wenyi Lu Zhuoqian Zhao Huanzhen Liu Yixuan Zhou Manli Hu Hui Wang Yingbin Yan Mingfeng Zhao Hongkai Zhang Mingjuan Du Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Prolonged haematologic toxicity in CAR-T-cell therapy: A review
J Cell Mol Med. 2023 Sep 13. doi: 10.1111/jcmm.17930. Online ahead of print.ABSTRACTChimeric antigen receptor-T-cell (CAR-T-cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune-mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR-T cells used and diseases treated as well as differences in the definition of PHT, its r...
Source: J Cell Mol Med - September 13, 2023 Category: Molecular Biology Authors: Qi Liu Tonglin Hu Hangchao Li Yingying Shen Dijiong Wu Baodong Ye Source Type: research
Peroxisome proliferator-activated receptors as therapeutic target for cancer
J Cell Mol Med. 2023 Sep 12. doi: 10.1111/jcmm.17931. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor family. There are three subtypes of PPARs, including PPAR-α, PPAR-β/δ and PPAR-γ. They are expressed in different tissues and act by regulating the expression of target genes in the form of binding to ligands. Various subtypes of PPAR have been shown to have significant roles in a wide range of biological processes including lipid metabolism, body energy homeostasis, cell proliferation and differentiation, bone formation, tiss...
Source: J Cell Mol Med - September 13, 2023 Category: Molecular Biology Authors: Yuqing Wang Feifei Lei Yiyun Lin Yuru Han Lei Yang Huabing Tan Source Type: research
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality
Trends Mol Med. 2023 Sep 11:S1471-4914(23)00189-2. doi: 10.1016/j.molmed.2023.08.004. Online ahead of print.ABSTRACTThe past decade has witnessed a revolution in cancer treatment by shifting from conventional therapies to immune checkpoint inhibitors (ICIs). These immunotherapies unleash the host immune system against the tumor and have achieved unprecedented durable remission. However, 80% of patients do not respond. This review discusses how bacteria are unexpected drivers that reprogram tumor immunity. Manipulating the microbiota impacts on tumor development and reprograms the tumor microenvironment (TME) of mice on imm...
Source: Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Nicolas Guillot Barnab é Roméo Shima Sepehri Manesh Gerard Milano Patrick Brest Laurence Zitvogel Paul Hofman Baharia Mograbi Source Type: research
Prolonged haematologic toxicity in CAR-T-cell therapy: A review
J Cell Mol Med. 2023 Sep 13. doi: 10.1111/jcmm.17930. Online ahead of print.ABSTRACTChimeric antigen receptor-T-cell (CAR-T-cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune-mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR-T cells used and diseases treated as well as differences in the definition of PHT, its r...
Source: Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Qi Liu Tonglin Hu Hangchao Li Yingying Shen Dijiong Wu Baodong Ye Source Type: research
Distribution modeling quantifies collective T < sub > H < /sub > cell decision circuits in chronic inflammation
Sci Adv. 2023 Sep 15;9(37):eadg7668. doi: 10.1126/sciadv.adg7668. Epub 2023 Sep 13.ABSTRACTImmune responses are tightly regulated by a diverse set of interacting immune cell populations. Alongside decision-making processes such as differentiation into specific effector cell types, immune cells initiate proliferation at the beginning of an inflammation, forming two layers of complexity. Here, we developed a general mathematical framework for the data-driven analysis of collective immune cell dynamics. We identified qualitative and quantitative properties of generic network motifs, and we specified differentiation dynamics b...
Source: Adv Data - September 13, 2023 Category: Epidemiology Authors: Philipp Burt Kevin Thurley Source Type: research
Peroxisome proliferator-activated receptors as therapeutic target for cancer
J Cell Mol Med. 2023 Sep 12. doi: 10.1111/jcmm.17931. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor family. There are three subtypes of PPARs, including PPAR-α, PPAR-β/δ and PPAR-γ. They are expressed in different tissues and act by regulating the expression of target genes in the form of binding to ligands. Various subtypes of PPAR have been shown to have significant roles in a wide range of biological processes including lipid metabolism, body energy homeostasis, cell proliferation and differentiation, bone formation, tiss...
Source: Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Yuqing Wang Feifei Lei Yiyun Lin Yuru Han Lei Yang Huabing Tan Source Type: research
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality
Trends Mol Med. 2023 Sep 11:S1471-4914(23)00189-2. doi: 10.1016/j.molmed.2023.08.004. Online ahead of print.ABSTRACTThe past decade has witnessed a revolution in cancer treatment by shifting from conventional therapies to immune checkpoint inhibitors (ICIs). These immunotherapies unleash the host immune system against the tumor and have achieved unprecedented durable remission. However, 80% of patients do not respond. This review discusses how bacteria are unexpected drivers that reprogram tumor immunity. Manipulating the microbiota impacts on tumor development and reprograms the tumor microenvironment (TME) of mice on imm...
Source: Trends in Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Nicolas Guillot Barnab é Roméo Shima Sepehri Manesh Gerard Milano Patrick Brest Laurence Zitvogel Paul Hofman Baharia Mograbi Source Type: research
Detection and quantitative analysis of tumor-associated tertiary lymphoid structures
This study reviews the latest research progress on TLS detection and quantification, proposes new directions for TLS assessment, and addresses issues for the quantitative application of TLSs in the clinic.PMID:37701955 | PMC:PMC10500099 | DOI:10.1631/jzus.B2200605
Source: J Zhejiang Univ Sci ... - September 13, 2023 Category: Science Authors: Man Yang Yurou Che Kezhen Li Zengyi Fang Simin Li Mei Wang Yiyao Zhang Zhu Xu Liping Luo Chuan Wu Xin Lai Weidong Wang Source Type: research
Prognostic significance and immune characteristics of GPR27 in gastric cancer
Aging (Albany NY). 2023 Sep 12;15. doi: 10.18632/aging.205023. Online ahead of print.ABSTRACTGastric cancer (GC) is one of the most typical cancerous neoplasms occurring in the digestive system. For advanced GC, immunotherapy is the final option for them to prolong survival time. Hence, we aimed to identify new molecular targets to enhance the immunotherapy response in GC individuals. Then we applied bioinformatic analysis to explore the expression profiles of G-protein-coupled receptor 27 (GPR27) transcription and GPR27 methylation. The associations between survival of GC patients and GPR27 transcription and methylation w...
Source: Aging - September 13, 2023 Category: Biomedical Science Authors: Jun Pan Yuanjun Gao Source Type: research
